Indications and characteristics of penile traction and vacuum erection devices.
Journal
Nature reviews. Urology
ISSN: 1759-4820
Titre abrégé: Nat Rev Urol
Pays: England
ID NLM: 101500082
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
accepted:
15
10
2021
pubmed:
13
11
2021
medline:
26
2
2022
entrez:
12
11
2021
Statut:
ppublish
Résumé
A variety of devices are available for the management of patients with erectile dysfunction, Peyronie's disease, penile dysmorphophobia, for support before and after penile prosthesis insertion, and after radical prostatectomy. Traction devices include, but are not limited to, Penimaster PRO (MSP Concept, Berlin, Germany), Andropenis and Andropeyronie (Andromedical, Madrid, Spain), and the Restorex (PathRight Medical, Plymouth, USA). The other type of devices are vacuum devices such the Osbon ErecAid (Timm Medical, MN, USA). Different devices are optimal for different clinical applications, and robust and contemporary clinical data show a variety of strengths and weaknesses for each device. Research currently favours the use of traction devices for improvement of penile curvature and erectile function in patients with Peyronie's disease compared with vacuum devices; Penimaster Pro and Restorex have been shown to be associated with the best outcomes in this indication. Vacuum devices are favoured for treatment of erectile dysfunction and penile length loss after radical prostatectomy; the Osbon ErecAid is the most well-studied device for this indication. Research into other uses of vacuum and traction devices, such as for penile dysmorphophobia or before and after penile prosthesis, is very limited. Compliance, cost and availability remain substantial challenges, and further high-quality evidence is required to clarify the role of traction devices in urology and sexual medicine.
Identifiants
pubmed: 34764451
doi: 10.1038/s41585-021-00532-7
pii: 10.1038/s41585-021-00532-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
84-100Informations de copyright
© 2021. Springer Nature Limited.
Références
Yuan, J. et al. Vacuum therapy in erectile dysfunction-science and clinical evidence. Int. J. Impot. Res. 22, 211–219 (2010).
pubmed: 20410903
doi: 10.1038/ijir.2010.4
Yuan, J. et al. Molecular mechanisms of vacuum therapy in penile rehabilitation: a novel animal study. Eur. Urol. 58, 773–780 (2010).
pubmed: 20674151
doi: 10.1016/j.eururo.2010.07.005
Lin, H. & Wang, R. The science of vacuum erectile device in penile rehabilitation after radical prostatectomy. Transl. Androl. Urol. 2, 61–66 (2013).
pubmed: 26816725
pmcid: 4708600
Kwok, A., Parnham, A. & Lucky, M. Penile lengthening and the treatment options available. Trends Urol. Mens. Heal. 10, 15–18 (2019).
doi: 10.1002/tre.720
Levine, L. A. & Newell, M. M. FastSize
pubmed: 18452379
doi: 10.1586/17434440.5.3.305
Gontero, P. et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie’s disease. Results of a phase II prospective study. J. Sex. Med. 6, 558–566 (2009).
pubmed: 19138361
doi: 10.1111/j.1743-6109.2008.01108.x
Martínez-Salamanca, J. I. et al. Acute phase Peyronie’s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J. Sex. Med. 11, 506–515 (2014).
pubmed: 24261900
doi: 10.1111/jsm.12400
Moncada, I. et al. Penile traction therapy with the new device ‘Penimaster PRO’ is effective and safe in the stable phase of Peyronie’s disease: a controlled multicentre study. BJU Int. 123, 694–702 (2019).
pubmed: 30365247
doi: 10.1111/bju.14602
Raheem, A. A. et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s disease. BJU Int. 106, 1178–1180 (2010).
pubmed: 20438558
doi: 10.1111/j.1464-410X.2010.09365.x
Macdonald, L., Armstrong, L., Lehmann, K., Acker, M. & Langille, G. Outcome analysis of patients with Peyronie’s disease who elect for vacuum erection device therapy. Can. Urol. Assoc. J. 23, 1–8 (2020).
Nowroozi, M. R. et al. Applying extender devices in patients with penile dysmorphophobia: assessment of tolerability, efficacy, and impact on erectile function. J. Sex. Med. 12, 1242–1247 (2015).
pubmed: 25809129
doi: 10.1111/jsm.12870
Gontero, P. et al. A pilot phase-II prospective study to test the “efficacy” and tolerability of a penile-extender device in the treatment of “short penis. BJU Int. 103, 793–797 (2009).
pubmed: 18990153
doi: 10.1111/j.1464-410X.2008.08083.x
Nikoobakht, M., Shahnazari, A., Rezaeidanesh, M., Mehrsai, A. & Pourmand, G. Effect of penile-extender device in increasing penile size in men with shortened penis: preliminary results. J. Sex. Med. 8, 3188–3192 (2011).
pubmed: 20102448
doi: 10.1111/j.1743-6109.2009.01662.x
Köhler, T. S. et al. A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int. 100, 858–862 (2007).
pubmed: 17822466
doi: 10.1111/j.1464-410X.2007.07161.x
Nason, G. J. et al. Efficacy of vacuum erectile devices (VEDs) after radical prostatectomy: the initial Irish experience of a dedicated VED clinic. Int. J. Impot. Res. 28, 205–208 (2016).
pubmed: 27225711
doi: 10.1038/ijir.2016.23
Raina, R. et al. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int. J. Impot. Res. 18, 77–81 (2006).
pubmed: 16107868
doi: 10.1038/sj.ijir.3901380
Canguven, O., Bailen, J., Fredriksson, W., Bock, D. & Burnett, A. L. Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction. J. Sex. Med. 6, 2561–2567 (2009).
pubmed: 19627462
doi: 10.1111/j.1743-6109.2009.01364.x
Zhang, D.-L. et al. Adding a vacuum erection device to regular use of Tadalafil improves penile rehabilitation after posterior urethroplasty. Asian J. Androl. 21, 1–4 (2019).
Sun, L., Peng, F. L., Yu, Z. L., Liu, C. L. & Chen, J. Combined sildenafil with vacuum erection device therapy in the management of diabetic men with erectile dysfunction after failure of first-line sildenafil monotherapy. Int. J. Urol. 21, 1263–1267 (2014).
pubmed: 25039272
doi: 10.1111/iju.12564
Veale, D. et al. Phenomenology of men with body dysmorphic disorder concerning penis size compared to men anxious about their penis size and to men without concerns: a cohort study. Body Image 13, 53–61 (2015).
pubmed: 25675864
doi: 10.1016/j.bodyim.2014.09.008
Dillon, B. E., Chama, N. B. & Honig, S. C. Penile size and penile enlargement surgery: a review. Int. J. Impot. Res. 20, 519–529 (2008).
pubmed: 18496548
doi: 10.1038/ijir.2008.14
Nehra, A. Pathophysiology of Peyronie’ s disease. Int. J. Impot. Res. Vol. 14, 406–410 (2002).
doi: 10.1038/sj.ijir.3900875
Ibrahim, A. et al. Evaluation of oral pentoxifylline, colchicine, and penile traction for the management of Peyronie’s disease. Sex. Med. 7, 459–463 (2019).
pubmed: 31445974
pmcid: 6963116
doi: 10.1016/j.esxm.2019.07.003
Emanu, J. C., Avildsen, I. K. & Nelson, C. J. Erectile dysfunction after radical prostatectomy: prevalence, medical treatments, and psychosocial interventions. Curr. Opin. Support. Palliat. Care 10, 102–107 (2016).
pubmed: 26808052
pmcid: 5005072
doi: 10.1097/SPC.0000000000000195
Davoudzadeh, E. P., Davoudzadeh, N. P., Margolin, E., Stahl, P. J. & Stember, D. S. Penile length: measurement technique and applications. Sex. Med. Rev. 6, 261–271 (2018).
pubmed: 29289534
doi: 10.1016/j.sxmr.2017.10.002
Liu, C., Lopez, D. S., Chen, M. & Wang, R. Penile rehabilitation therapy following radical prostatectomy: a meta-analysis. J. Sex. Med. 14, 1496–1503 (2017).
pubmed: 29122494
doi: 10.1016/j.jsxm.2017.09.020
Cho, M. C., Song, W. H. & Paick, J. S. Suppression of cavernosal fibrosis in a rat model. Sex. Med. Rev. 6, 572–582 (2018).
pubmed: 29631978
doi: 10.1016/j.sxmr.2018.02.007
Lin, H., Liu, C. & Wang, R. Effect of penile traction and vacuum erectile device for Peyronie’s disease in an animal model. J. Sex. Med. 14, 1270–1276 (2017).
pubmed: 28923308
doi: 10.1016/j.jsxm.2017.08.011
Lin, H. C., Yang, W. L., Zhang, J. L., Dai, Y. T. & Wang, R. Penile rehabilitation with a vacuum erectile device in an animal model is related to an antihypoxic mechanism: blood gas evidence. Asian J. Androl. 15, 387–390 (2013).
pubmed: 23564044
pmcid: 3739658
doi: 10.1038/aja.2013.18
Leungwattanakij, S. et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J. Androl. 24, 239–245 (2003).
pubmed: 12634311
doi: 10.1002/j.1939-4640.2003.tb02668.x
Canguven, O., Lagoda, G., Sezen, S. F. & Burnett, A. L. Losartan preserves erectile function after bilateral cavernous nerve injury via antifibrotic mechanisms in male rats. J. Urol. 181, 2816–2822 (2009).
pubmed: 19375729
doi: 10.1016/j.juro.2009.01.097
Welliver, R. C., Mechlin, C., Goodwin, B., Alukal, J. P. & Mccullough, A. R. A pilot study to determine penile oxygen saturation before and after vacuum therapy in patients with erectile dysfunction after radical prostatectomy. J. Sex. Med. 11, 1071–1077 (2014).
pubmed: 24506138
doi: 10.1111/jsm.12445
Chung, E., De Young, L., Solomon, M. & Brock, G. B. Peyronie’s disease and mechanotransduction: an in vitro analysis of the cellular changes to Peyronie’s disease in a cell-culture strain system. J. Sex. Med. 10, 1259–1267 (2013).
pubmed: 23421851
doi: 10.1111/jsm.12082
Milenkovic, U., Albersen, M. & Castiglione, F. The mechanisms and potential of stem cell therapy for penile fibrosis. Nat. Rev. Urol. 16, 79–97 (2019).
pubmed: 30367131
doi: 10.1038/s41585-018-0109-7
Li, J. et al. Reduction in Peyronie’s-like plaque size using a vacuum erection device in a rat model of Peyronie’s disease via the TGF-β/SMAD signalling pathway. Andrologia 50, 1–8 (2018).
doi: 10.1111/and.13051
Qian, A., Meals, R. A., Rajfer, J. & Gonzalez-Cadavid, N. F. Comparison of gene expression profiles between Peyronie’s disease and Dupuytren’s contracture. Urology 64, 399–404 (2004).
pubmed: 15302515
doi: 10.1016/j.urology.2004.04.006
Usta, M. F. & Ipekci, T. Penile traction therapy for Peyronie’s disease — what’s the evidence? Transl. Androl. Urol. 5, 303–309 (2016).
pubmed: 27298777
pmcid: 4893512
doi: 10.21037/tau.2016.03.25
Phé, V. & Rouprêt, M. Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies. Diabetes Metab. 38, 1–13 (2012).
pubmed: 22056307
doi: 10.1016/j.diabet.2011.09.003
Takahashi, K., Ghatei, M. A., Lam, H. C., O’Halloran, D. J. & Bloom, S. R. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 33, 306–310 (1990).
pubmed: 2198188
doi: 10.1007/BF00403325
Castela, Â. & Costa, C. Molecular mechanisms associated with diabetic endothelial-erectile dysfunction. Nat. Rev. Urol. 13, 266–274 (2016).
pubmed: 26878803
doi: 10.1038/nrurol.2016.23
Lee, M. & Sharifi, R. Non-invasive management options for erectile dysfunction when a phosphodiesterase type 5 inhibitor fails. Drugs Aging 35, 175–187 (2018).
pubmed: 29464656
doi: 10.1007/s40266-018-0528-4
Ziegelmann, M. J. et al. Clinical experience with penile traction therapy among men undergoing collagenase clostridium histolyticum for Peyronie disease. Urology 104, 102–109 (2017).
pubmed: 28347795
doi: 10.1016/j.urology.2017.01.054
Ziegelmann, M. et al. Outcomes of a novel penile traction device in men with Peyronie’s disease: a randomized, single-blind, controlled trial. J. Urol. 202, 599–610 (2019).
pubmed: 30916626
doi: 10.1097/JU.0000000000000245
Alom, M., Sharma, K. L., Toussi, A., Kohler, T. & Trost, L. Efficacy of combined collagenase Clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie’s disease. J. Sex. Med. 16, 891–900 (2019).
pubmed: 30956106
doi: 10.1016/j.jsxm.2019.03.007
Joseph, J. et al. Outcomes of RestoreX penile traction therapy in men with Peyronie’s disease: results from open label and follow-up phases. J. Sex. Med. 17, 2462–2471 (2020).
pubmed: 33223425
doi: 10.1016/j.jsxm.2020.10.003
Wymer, K., Kohler, T. & Trost, L. Comparative cost-effectiveness of surgery, collagenase Clostridium histolyticum, and penile traction therapy in men with Peyronie’s disease in an era of effective clinical treatment. J. Sex. Med. 16, 1421–1432 (2019).
pubmed: 31351851
doi: 10.1016/j.jsxm.2019.06.010
Rybak, J., Papagiannopoulos, D. & Levine, L. A retrospective comparative study of traction therapy vs. no traction following tunica albuginea plication or partial excision and grafting for Peyronie’s disease: measured lengths and patient perceptions. J. Sex. Med. 9, 2396–2403 (2012).
pubmed: 22900621
doi: 10.1111/j.1743-6109.2012.02849.x
Abern, M. R., Larsen, S. & Levine, L. A. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie’s disease. J. Sex. Med. 9, 288–295 (2012).
pubmed: 22024053
doi: 10.1111/j.1743-6109.2011.02519.x
Cowper, M. G., Burkett, C. B., Le, T. V., Scherzer, N. & Hellstrom, W. J. G. Penile stretching as a treatment for Peyronie’s disease: a review. Sex. Med. Rev. 7, 508–515 (2019).
pubmed: 30612978
doi: 10.1016/j.sxmr.2018.11.002
Jorissen, C., De Bruyna, H., Baten, E. & Van Renterghem, K. Clinical outcome: patient and partner satisfaction after penile implant surgery. Curr. Urol. 13, 94–100 (2019).
pubmed: 31768176
pmcid: 6872984
doi: 10.1159/000499286
Tran, H., Goldfarb, R., Ackerman, A. & Valenzuela, R. J. Penile lengthening, girth, and size preservation at the time of penile prosthesis insertion. Sex. Med. Rev. 5, 403–412 (2017).
pubmed: 28238678
doi: 10.1016/j.sxmr.2016.11.005
Levine, L. A. & Rybak, J. Traction therapy for men with shortened penis prior to penile prosthesis implantation: a pilot study. J. Sex. Med. 8, 2112–2117 (2011).
pubmed: 21492409
doi: 10.1111/j.1743-6109.2011.02285.x
Canguven, O. et al. Is the daily use of vacuum erection device for a month before penile prosthesis implantation beneficial? A randomized controlled trial. Andrology 5, 103–106 (2017).
pubmed: 27654466
doi: 10.1111/andr.12258
Tsambarlis, P. N., Chaus, F. & Levine, L. A. Successful placement of penile prostheses in men with severe corporal fibrosis following vacuum therapy protocol. J. Sex. Med. 14, 44–46 (2017).
pubmed: 27938991
doi: 10.1016/j.jsxm.2016.11.304
Antonini, G. et al. Inflatable penile prosthesis placement, scratch technique and postoperative vacuum therapy as a combined approach to definitive treatment of Peyronie’s disease. J. Urol. 200, 642–647 (2018).
pubmed: 29678456
doi: 10.1016/j.juro.2018.04.060
Koehler, N. et al. Erectile dysfunction after radical prostatectomy: the impact of nerve-sparing status and surgical approach. Int. J. Impot. Res. 24, 155–160 (2012).
pubmed: 22551824
doi: 10.1038/ijir.2012.8
Castiglione, F., Ralph, D. J. & Muneer, A. Surgical techniques for managing post-prostatectomy erectile dysfunction. Curr. Urol. Rep. 18, 1–9 (2017).
doi: 10.1007/s11934-017-0735-2
Raina, R., Pahlajani, G., Agarwal, A., Jones, S. & Zippe, C. Long-term potency after early use of a vacuum erection device following radical prostatectomy. BJU Int. 106, 1719–1722 (2010).
pubmed: 20394611
doi: 10.1111/j.1464-410X.2010.09360.x
Dalkin, B. L. & Christopher, B. A. Preservation of penile length after radical prostatectomy: early intervention with a vacuum erection device. Int. J. Impot. Res. 19, 501–504 (2007).
pubmed: 17657210
doi: 10.1038/sj.ijir.3901561
Ghanem, H., Glina, S., Assalian, P. & Buvat, J. Position paper: management of men complaining of a small penis despite an actually normal size. J. Sex. Med. 10, 294–303 (2013).
pubmed: 22512935
doi: 10.1111/j.1743-6109.2012.02725.x
Kayes, O., Shabbir, M., Ralph, D. & Minhas, S. Therapeutic strategies for patients with micropenis or penile dysmorphic disorder. Nat. Rev. Urol. 9, 499–507 (2012).
pubmed: 22890302
doi: 10.1038/nrurol.2012.150
Kessler, A., Sollie, S., Challacombe, B., Briggs, K. & Van Hemelrijck, M. The global prevalence of erectile dysfunction: a review. BJU Int. 124, 587–599 (2019).
doi: 10.1111/bju.14813
Colson, M. H., Cuzin, B., Faix, A., Grellet, L. & Huyghes, E. Current epidemiology of erectile dysfunction, an update. Sexologies 27, e7–e13 (2018).
doi: 10.1016/j.sexol.2018.01.018
Price, D. E. et al. The management of impotence in diabetic men by vacuum tumescence therapy. Diabet. Med. 8, 964–967 (1991).
pubmed: 1838050
doi: 10.1111/j.1464-5491.1991.tb01538.x
Dutta, T. C. & Eid, J. F. Vacuum constriction devices for erectile dysfunction: a long-term, prospective study of patients with mild, moderate, and severe dysfunction. Urology 54, 891–893 (1999).
pubmed: 10565753
doi: 10.1016/S0090-4295(99)00264-2
Derouet, H., Caspari, D., Rohde, V., Rommel, G. & Ziegler, M. Treatment of erectile dysfunction with external vacuum devices. Andrologia 31, 89–94 (1999).
pubmed: 10643525
doi: 10.1111/j.1439-0272.1999.tb01456.x
Soderdahl, D. W., Thrasher, J. B. & Hansberry, K. L. Intracavernosal drug-induced erection therapy versus external vacuum devices in the treatment of erectile dysfunction. Br. J. Urol. 79, 952–957 (1997).
pubmed: 9202565
doi: 10.1046/j.1464-410X.1997.00147.x
Turner, L. A. et al. Twelve-month comparison of two treatments for erectile dysfunction: self-injection versus external vacuum devices. Urology 39, 139–144 (1992).
pubmed: 1736506
doi: 10.1016/0090-4295(92)90270-7
Chen, J., Sofer, M., Kaver, I., Matzkin, H. & Greenstein, A. Concomitant use of sildenafil and a vacuum entrapment device for the treatment of erectile dysfunction. J. Urol. 171, 292–295 (2004).
pubmed: 14665897
doi: 10.1097/01.ju.0000098460.02560.fe
Rivas, D. A., Chancellor, M. B. Complications associated with the use of vacuum constriction devices for erectile dysfunction in the spinal cord injured population. J. Am. Paraplegia Soc. 17, 136–139 (2017).
doi: 10.1080/01952307.1994.11735923
Deng, H. et al. Phosphodiesterase-5 inhibitors and vacuum erection device for penile rehabilitation after laparoscopic nerve-preserving radical proctectomy for rectal cancer: a prospective controlled trial. Am. J. Mens. Health 11, 641–646 (2017).
pubmed: 27561925
doi: 10.1177/1557988316665084
NHS Business Services Authority. NHSBSA Drug Tariffs. NHS https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff (2021).
(LMEN) London Medicine Evaluation Network. Medicines Optimisation Programme Board (MOPB) Report on Collagenase Clostridium Histolyticum for Peyronie’s Disease. NHS https://westessexccg.nhs.uk/your-health/medicines-optimisation-and-pharmacy/high-cost-drug-policies-and-pro-formas/collagenase-clostridium-histolyticum/2917-peyronie-s-disease/file (2019).
Adam, S. Treatment for Impotence. Health Service Circular: treatment for impotence. NHS http://www.westsuffolkccg.nhs.uk/wp-content/uploads/2013/01/HSC-1999-177-Treatment-for-Impotence.pdf (2000).